Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coherus Refiles US On-Body Pegfilgrastim, With Potential For 2023 Approval

Company Indicates That Quick Resolution Of CRL Could Lead To FDA Nod By Year End

Executive Summary

Coherus BioSciences has swiftly returned a filing for its on-body pegfilgrastim biosimilar candidate to the US Food and Drug Administration, while hitting a milestone for its Cimerli biosimilar to Lucentis (ranibizumab).

You may also be interested in...



Coherus Eyeing US Pegfilgrastim Bulk With On-Body Injector Approval

Coherus has roared into the new year with a US FDA approval that has long been on its radar: the company’s debut rival to the Neulasta Onpro on-body injector device using Coherus’ Udenyca (pegfilgrastim-cbqv) biosimilar.

More Than Just Humira: US Biosimilars Enjoy An Eventful 2023

The launch of competition to Humira was the main event for US biosimilars this year – but a number of other key developments also took place in 2023, including settlements on Stelara that set up a series of launches in 2025, as well as first approvals for ustekinumab, natalizumab and tocilizumab biosimilars.

More Than Just Humira: US Biosimilars Enjoy An Eventful 2023

The launch of competition to Humira was the main event for US biosimilars this year – but a number of other key developments also took place in 2023, including settlements on Stelara that set up a series of launches in 2025, as well as first approvals for ustekinumab, natalizumab and tocilizumab biosimilars.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel